New Drugs on the Block-Emerging Treatments for Nonalcoholic Steatohepatitis.
Ontology highlight
ABSTRACT: Patients with nonalcoholic steatohepatitis (NASH) are at higher risk of progression to advanced stages of fibrosis, cirrhosis, hepatocellular carcinoma and other end-stage liver disease complications. When addressing treatment of NASH, we have limited approved options, and the mainstay of therapy is lifestyle intervention. Extensive research and revelation in the field of pathogenesis of NASH has offered new possibilities of treatment and emerging new drugs that are being tested currently in numerous preclinical and clinical trials. These drugs target almost all steps in the pathogenesis of NASH to improve insulin sensitivity, glucose and lipid metabolism, to inhibit de novo lipogenesis and delivery of lipids to the liver, and to influence apoptosis, inflammation and fibrogenesis. A
SUBMITTER: Stojsavljevic-Shapeski S
PROVIDER: S-EPMC7868699 | biostudies-literature | 2021 Feb
REPOSITORIES: biostudies-literature
ACCESS DATA